Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus.
Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Tada T, Nakamura S, Yasuda S, Toyoda H, Loomba R, Izumi N. Tamaki N, et al. Among authors: tsuji k. Hepatol Commun. 2022 Mar;6(3):461-472. doi: 10.1002/hep4.1833. Epub 2021 Oct 22. Hepatol Commun. 2022. PMID: 34676692 Free PMC article.
Liver disease in hepatitis C virus carriers identified at blood donation and their outcomes with or without interferon treatment: Study on 1019 carriers followed for 5-10 years.
Mizui M, Tanaka J, Katayama K, Nakanishi T, Obayashi M, Aimitsu S, Yoshida T, Inoue J, Yokoyama T, Tsuji K, Arataki K, Yamaguchi S, Miura T, Kitamoto M, Takezaki E, Orimen S, Sakata T, Kamada K, Maruhashi A, Tamura T, Nakamura T, Ishida K, Teramen K, Miyakawa Y, Yoshizawa H. Mizui M, et al. Among authors: tsuji k. Hepatol Res. 2007 Dec;37(12):994-1001. doi: 10.1111/j.1872-034X.2007.00157.x. Epub 2007 Jul 11. Hepatol Res. 2007. PMID: 17627620
Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy.
Jeong S, Kawakami Y, Kitamoto M, Ishihara H, Tsuji K, Aimitsu S, Kawakami H, Uka K, Takaki S, Kodama H, Waki K, Imamura M, Aikata H, Takahashi S, Chayama K. Jeong S, et al. Among authors: tsuji k. J Gastroenterol Hepatol. 2008 Apr;23(4):541-5. doi: 10.1111/j.1440-1746.2008.05356.x. J Gastroenterol Hepatol. 2008. PMID: 18397484 Clinical Trial.
Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial.
Kawaoka T, Kawakami Y, Tsuji K, Ito H, Kitamoto M, Aimitsu S, Kawakami H, Jeong SC, Imamura M, Aikata H, Takahashi S, Chayama K. Kawaoka T, et al. Among authors: tsuji k. J Gastroenterol Hepatol. 2009 Mar;24(3):366-71. doi: 10.1111/j.1440-1746.2008.05650.x. Epub 2008 Nov 20. J Gastroenterol Hepatol. 2009. PMID: 19032459 Clinical Trial.
Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.
Yokoyama S, Kawakami Y, Imamura M, Hayes CN, Kohno H, Kohno H, Tsuji K, Aisaka Y, Kira S, Yamashina K, Nonaka M, Takahashi S, Moriya T, Kitamoto M, Aimitsu S, Nakanishi T, Kawakami H, Chayama K. Yokoyama S, et al. Among authors: tsuji k. J Gastroenterol Hepatol. 2015 Feb;30(2):337-44. doi: 10.1111/jgh.12706. J Gastroenterol Hepatol. 2015. PMID: 25091289
IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C.
Mori N, Imamura M, Kawakami Y, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Hayes CN, Aikata H, Miki D, Ochi H, Honda Y, Takaki S, Tsuji K, Chayama K; Hiroshima Liver Study Group. Mori N, et al. Among authors: tsuji k. Hepatol Res. 2017 Mar;47(3):E5-E13. doi: 10.1111/hepr.12715. Epub 2016 Apr 21. Hepatol Res. 2017. PMID: 27027531
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hatooka M, Kawaoka T, Aikata H, Morio K, Kobayashi T, Hiramatsu A, Imamura M, Kawakami Y, Murakami E, Waki K, Honda Y, Mori N, Takaki S, Tsuji K, Kohno H, Kohno H, Moriya T, Nonaka M, Hyogo H, Aisaka Y, Chayama K. Hatooka M, et al. Among authors: tsuji k. Anticancer Res. 2016 Jul;36(7):3523-9. Anticancer Res. 2016. PMID: 27354618
Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
Morio K, Imamura M, Kawakami Y, Morio R, Kobayashi T, Yokoyama S, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Makokha GN, Hayes CN, Aikata H, Miki D, Ochi H, Honda Y, Mori N, Takaki S, Tsuji K, Chayama K. Morio K, et al. Among authors: tsuji k. J Gastroenterol Hepatol. 2017 Mar;32(3):645-650. doi: 10.1111/jgh.13511. J Gastroenterol Hepatol. 2017. PMID: 27513614
Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
Morio R, Imamura M, Kawakami Y, Morio K, Kobayashi T, Yokoyama S, Kimura Y, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Nelson Hayes C, Aikata H, Takahashi S, Miki D, Ochi H, Mori N, Takaki S, Tsuji K, Chayama K. Morio R, et al. Among authors: tsuji k. J Gastroenterol. 2017 Apr;52(4):504-511. doi: 10.1007/s00535-016-1255-4. Epub 2016 Sep 8. J Gastroenterol. 2017. PMID: 27631593 Clinical Trial.
Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.
Itakura J, Kurosaki M, Hasebe C, Osaki Y, Joko K, Yagisawa H, Sakita S, Okushin H, Satou T, Hisai H, Abe T, Tsuji K, Tamada T, Kobashi H, Mitsuda A, Ide Y, Ogawa C, Tsuruta S, Takaguchi K, Murakawa M, Asahina Y, Enomoto N, Izumi N. Itakura J, et al. Among authors: tsuji k. PLoS One. 2016 Oct 24;11(10):e0165339. doi: 10.1371/journal.pone.0165339. eCollection 2016. PLoS One. 2016. PMID: 27776192 Free PMC article.
2,234 results